Typed or printed name

Maribel Mendez

May 23, 2005

#### P. 1

MAY **2 3** 2005

RECEIVED **CENTRAL FAX CENTER** 

PTC/SE/21 (09-04)
Approved for use through 07/31/2005. CMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of Information unless it displays a welld OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co Application Number 10/790.260 Filing Date TRANSMITTAL March 02, 2004 First Named Inventor FORM Pascal DESMAZEAU et al. Art Unit 1653 Examiner Name LUKTON, David (to be used for all correspondence after Initial fillnd) Attorney Docket Number \$198007 US CNT Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) | • | Petition Amendment/Repty Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Cartillad Copy of Priority Document(s) 1. RESPONSE TO RESTRICTION/ELECTION REQUIREMENT - 9 PGS. Reply to Missing Parts/ Incomplete Application
Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature larann Printed name Balaram Gupta Date Reg. No. L0178 May 23, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 Total No. of Pages Transmitted: 4 pgs. Signature Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the CNef Internation Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22319-1450, OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND 70: Commissioner for Patente, P.O. Box 1450, Alexandria, VA 22313-1450.

MAY 2 3 2005

**PATENT** 

Docket No.: ST98007-US-CNT

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Pascal Desmazeau, et al.

Examiner:

Lukton, David

Art Unit:

1653

Serial No.: 10/790,260

Filed:

March 2, 2004

TELEFAX CERTIFICATE

Title:

STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING

SAME

I hereby certify that this correspondence is being transmitted via facsimile at 703-872-9306 to the Commissioner for Patents, Washington, D.C. 20231, on 5-23-05

Date of Transpringsion
Signature
Signature

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Response to Restriction/Election Requirement Under 35 U.S.C. § 121

Sir:

This is in response to the Office Action, dated, April 25, 2005, having a response due by, May 25, 2005 in the above-identified patent application. It is respectfully requested that the following provisional election, and the remarks be entered in this case.

## PROVISIONAL ELECTION:

Applicants provisionally elect with traverse the invention Group I, claims 18-30, and 32-34, drawn to compounds, methods of making compounds, and a binary mixture of compounds.

#### ELECTION OF A COMPOUND WITHIN ELECTED SUB-SPECIES:

Applicants provisionally elect with traverse a single compound falling within the scope of invention Group I to be 3"-ethoxycarbonyl-2"-aminopyrido [2,3- $5\gamma$ ,5 $\delta$ ]pristinamycin I<sub>E</sub>, which is also described in Example 2 at page 41 of the specification.

ST98007-US-CNT